PeterAKaufmanMD

Oncology • Burlington, VT

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine, Dartmouth Medical School

Join to view full profile

Dr. Kaufman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kaufman's full profile

Already have an account?

Office
Beaumont Ave
UVM Cancer Center
Burlington, VT 05403
Phone+1 603-653-6181
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1989
Duke University HospitalResidency, Internal Medicine, 1983 - 1986
New York University School of MedicineClass of 1983

Certifications & Licensure

VT State Medical License 1993 - 2024
NH State Medical License 1992 - 2020
NC State Medical License 1987 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Long-term Mammography Screening Trends and Predictors of Return to Screening after the COVID-19 Pandemic: Results from a Statewide Registry.
Brian L Sprague, Sarah A Nowak, Thomas P Ahern, Catherine Odde, Pamela M Vacek, Sally D Herschorn, Peter A Kaufman, Hannah Perry, Michelle M Sowden, Donald L Weaver> ;Radiology. Imaging Cancer. 2024 May 1
Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC.
Farrah B Khan, Pamela C Gibson, Scott Anderson, Sarah Wagner, Bernard F Cole, Peter Kaufman, C Matthew Kinsey> ;JTO Clinical and Research Reports. 2024 Mar 1
Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast c...
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Peter A Kaufman> ;Breast Cancer Research and Treatment. 2024 May 1
1 citations
Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer.
Matthew P Goetz, Erika P Hamilton, Mario Campone, Sara A Hurvitz, Javier Cortes, Stephen Johnston, Antonio Llombart-Cussac, Peter A Kaufman, Masakazu Toi, Guy Jerusale...> ;Clinical Cancer Research. 2023 Oct 27
Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer.
Xu Cao, Kristen E Muller, Mary D Chamberlin, Jiang Gui, Peter A Kaufman, Gary N Schwartz, Roberta M diFlorio-Alexander, Brian W Pogue, Keith D Paulsen, Shudong Jiang> ;Clinical Cancer Research. 2023 Dec 1
Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer.
Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar, Jonathan D Marotti, Mary D Chamberlin, Bradley A Arrick, Grace Makari-Judson, Matthew P Goetz, Shannon M Soucy, F...> ;Clinical Cancer Research. 2023 May 15
Cumulative 6-Year Risk of Screen-Detected Ductal Carcinoma In Situ by Screening Frequency.
Brian L Sprague, Shuai Chen, Diana L Miglioretti, Charlotte C Gard, Jeffrey A Tice, Rebecca A Hubbard, Erin J Aiello Bowles, Peter A Kaufman, Karla Kerlikowske> ;JAMA Network Open. 2023 Feb 1
Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug ...
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Kaufman, P.> ;Breast Cancer. 2023 Jan 1
1 citations
Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.
Peter A Kaufman, Edward Neuberger, Naomi R M Schwartz, Shu Wang, Yutong Liu, Ling-I Hsu, Karen Bartley, Matthew T Blahna, Brian T Pittner, Gabriel Wong, Carey Anders> ;Frontiers in Oncology. 2023 Jan 1
20 citations
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Pha...
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D Pegram, Thomas Bachelot, Gail S Wright, Cristina Saura, Santiag...> ;Journal of Clinical Oncology. 2023 Jan 10
3 citations
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer
Patrick Neven, Stephen R. D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh,...> ;Clinical Cancer Research. 2021 Nov 1
42 citations
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer...
Roisin M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown-Glaberman, Jennifer S. Winn, Bryan A. Faller, Adedayo A. O...> ;Journal of Clinical Oncology. 2021 Aug 6
3 citations
Cancer Care in the Wake of a Cyberattack: How to Prepare and What to Expect.
Steven Ades, Diego Adrianzen Herrera, Timothy Lahey, Alissa A. Thomas, Sakshi Jasra, Maura Barry, Julian Sprague, Kim Dittus, Timothy B Plante, Jamie A. Kelly, Peter A...> ;JCO Oncology Practice. 2021 Aug 2
Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Shayma Kazmi, Debanjana Chatterjee, Dheeraj Raju, Rob Hauser, Peter A Kaufman> ;Breast Cancer Research and Treatment. 2021 Jun 1
64 citations
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, D. R. D'Adamo, Gursel Aktan, Michaela L. Tsai, Ruth O'Regan, Peter A. Kaufman, Sharon Wilks, Eleni Andreopoulou...> ;Clinical Cancer Research. 2021 Jun 1
5 citations
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
Peter A. Kaufman, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Melody A. Cobleigh, Sandra M. Swain, Debu Tripathy,...> ;Breast Cancer Research and Treatment. 2021 Feb 28
6 citations
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Shayma Kazmi, Debanjana Chatterjee, Dheeraj Raju, Rob Hauser, Peter A Kaufman> ;Breast Cancer Research and Treatment. 2020 Nov 1
1 citations
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast can...
Mary D. Chamberlin, Jason D. Wells, Kevin Shee, Jennifer R. Bean, Jonathan D. Marotti, Wendy A. Wells, Heidi W. Trask, Fred W. Kolling, Ananta Bhatt, Peter A. Kaufman,...> ;Breast Cancer Research and Treatment. 2020 Jun 19
12 citations
Effect of neuromuscular electrical stimulation on skeletal muscle size and function in patients with breast cancer receiving chemotherapy
Michael J. Toth, Thomas B. Voigt, Timothy W. Tourville, Shannon M. Prior, Blas A. Guigni, Axel V. Schlosberg, Isaac B. Smith, Peter A. Kaufman, Marie E. Wood, Hibba tu...> ;Journal of Applied Physiology. 2020 May 7
15 citations
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
Melody A. Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason,...> ;Clinical Cancer Research. 2020 Mar 1
101 citations
Enhancing global access to cancer medicines.
Javier Cortes, Jose Perez-Garcia, Antonio Llombart-Cussac, Giuseppe Curigliano, Nagi S. El Saghir, Fatima Cardoso, Carlos H. Barrios, Shama Wagle, Javier Roman, Nadia ...> ;CA. 2020 Mar 1
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Peter A Kaufman, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Valerie Andre, Clemens Stoffregen, Sarah Shekarriz, Gregory L Price, Gebra Cuyun Carter...> ;The Oncologist. 2020 Feb 1
21 citations
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Debu Tripathy, Adam Brufsky, Melody Cobleigh, Mohammad Jahanzeb, Peter A Kaufman, Ginny Mason, Joyce O'Shaughnessy, Hope S Rugo, Sandra M Swain, Denise A Yardley, Laur...> ;The Oncologist. 2020 Feb 1
485 citations
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH ...
George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, EM Gr...> ;JAMA Oncology. 2020 Jan 1
4 citations
Health Through Activity: Initial Evaluation of an In-Home Intervention for Older Adults With Cancer.
Kathleen Doyle Lyons, Martha L. Bruce, Jay G. Hull, Peter A. Kaufman, Zhongze Li, Diane M. Stearns, Frederick Lansigan, Mary D. Chamberlin, Alexander D. Fuld, Stephen ...> ;The American Journal of Occupational Therapy. 2019 Sep 1
Join now to see all

Lectures

Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Breast Cancer: What We Know TodayJune 2nd, 2022
Laekna Therapeutics Announces Dosing of First Patients in the U.S. And China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast CancerMay 26th, 2022
UVM Students Contribute to Groundbreaking Cancer ResearchJune 9th, 2021

Hospital Affiliations

University of Vermont Medical CenterBurlington, Vermont